At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Jul 14, 2026 at 16:53 ET
Celcuity announced FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation, based on Phase 3 VIKTORIA-1 data showing a 76% reduction in risk of progression or death. This is the company's first approved product, transforming it from a clinical-stage biotech to a commercial-stage company, with launch expected in late Q3 2026.
- FDA approved REVTORPYK (gedatolisib) for HR+/HER2- locally advanced or metastatic breast cancer without PIK3CA mutation
- First and only FDA-approved therapy inhibiting all class I PI3K isoforms and mTORC1/2
- Phase 3 VIKTORIA-1: REVTORPYK triplet reduced risk of progression or death by 76% (HR=0.24) vs fulvestrant
- Median PFS: 9.3 months (triplet) vs 2.0 months (fulvestrant); ORR 32% vs 1%
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access